Top Story
September 23, 2017
Imeglimin, part of a new class of oral agents for type 2 diabetes that target mitochondrial bioenergetics, was found to be safe and effective in Japanese adults, according to results presented at the European Association for the Study of Diabetes Annual Meeting.
Kohjiro
Ueki, MD, PhD, director of the Diabetes Research Center at the National Center for Global Health and Medicine in Tokyo, and colleagues conducted a phase 2b randomized, double-blind, placebo-controlled study of imeglimin in Japanese adults with type 2 diabetes (n = 299). Participants were randomly assigned to one of three doses of twice-daily imeglimin (500 mg, 1000 mg and 1500 mg) or placebo for 24 weeks.